4.0 Article

Think beyond the Skin: 2014 Canadian Expert Opinion Paper on Treating to Target in Plaque Psoriasis

期刊

出版社

SAGE PUBLICATIONS INC
DOI: 10.2310/7750.2014.13151

关键词

-

资金

  1. AbbVie
  2. Novartis
  3. Actelion
  4. Amgen
  5. Astellas
  6. Bio-K
  7. Celgene
  8. Galderma
  9. Janssen
  10. LEO Pharma
  11. Merck/Schering
  12. Pfizer
  13. Roche
  14. Valeant
  15. Abbott
  16. Centocor
  17. Isotechnika
  18. Lilly
  19. Merck
  20. Ortho Biotech
  21. Wyeth
  22. Eli Lilly

向作者/读者索取更多资源

Objective: Explore the feasibility of Treat to Target in the area of psoriasis as seen in other therapeutic areas such as hypertension, hyperlipidemia, diabetes and rheumatoid arthritis. Methods: Review validated, measurable targets for psoriasis, including physician global assessment (PGA), psoriasis area and severity index (PASI) and dermatology life quality index (DLQI). Examine principles brought forth in the published European consensus on psoriasis and develop a Canadian consensus on Treat to Target in psoriasis. Results: As PASI and DLQI are not routinely used in the community setting, we are recommending target at a PGA of zero (clear). Conclusion: Recommend that the target is a PGA of zero (clear) as it provides a simple and measurable result that the patient and physician can clearly understand.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据